Applied Filters
LSIPR 50 2018: Levelling the medicines playing field
Speaking to LSIPR Leena Menghaney, regional head of Médecins Sans Frontières’ Access Campaign in South Asia, explains the importance of a balanced IP policy in fostering healthy generic competition.
Protecting patients, and patents
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
Getting into the biosimilars action
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.
From London to Amsterdam: what the EMA’s move means for medicines regulation
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
LSIPR 50 2017: Jane Philpott
Jane Philpott was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the government and policy section, as LSIPR reports.
LSIPR 50 2017: Galit Gonen
Galit Gonen was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.
Data analysis: the highs and lows of generic-filed IPRs
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner.
New framework for Spanish patentees
Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.
The challenges of patenting cell therapies
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
IP and investment: put your money where your mouth is
Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.
